Contraception and preconception counseling in special populations

References

• Cohen LS, Altshuler LL, Harlow BL et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA295(5), 499–507 (2006). Erratum in: JAMA296(2), 170 (2006).
   PubMed Web of Science ®Google Scholar
• Koke SC, Brown EB, Miner CM. Safety and efficacy of fluoxetine in patients who receive oral contraceptive therapy. Am. J. Obstet. Gynecol.187(3), 551–555 (2002).
   PubMed Web of Science ®Google Scholar
• Westhoff C, Truman C, Kalmuss D et al. Depressive symptoms and Norplant contraceptive implants. Contraception57, 241–245 (1998).
   PubMed Web of Science ®Google Scholar
• Westhoff C, Truman C, Kalmuss D et al. Depressive symptoms and depo-provera. Contraception57, 237–240 (1998).
   PubMed Web of Science ®Google Scholar
• Tsai R, Schaffir J. Effect of depot medroxyprogesterone acetate on postpartum depression. Contraception82(2), 174–177 (2010).
   PubMed Web of Science ®Google Scholar
• Young EA, Kornstein SG, Harvey AT et al. Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression. Psychoneuroendocrinology32, 843–853 (2007).
   PubMed Web of Science ®Google Scholar
• Velligan DI, Weiden PJ, Sajatovic M et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. J. Clin. Psychiatry70(Suppl. 4), 1–46 (2009).
   PubMed Web of Science ®Google Scholar
• US FDA. Federal register. 44, 37434–37467 (1980).
   Google Scholar
• Wurst KE, Poole C, Ephross SA, Olshan AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res. A Clin. Mol. Teratol.88(3), 159–170 (2010).
   PubMed Web of Science ®Google Scholar
• Koke SC, Brown EB, Miner CM. Safety and efficacy of fluoxetine in patients who receive oral contraceptive therapy. Am. J. Obstet Gynecol.187(3), 551–555 (2002).
   PubMed Web of Science ®Google Scholar
• Pietrzak B, Bobrowska K, Jabiry-Zieniewicz Z et al. Oral and transdermal hormonal contraception in women after kidney transplantation. Transplant. Proc.39(9), 2759–2762 (2007).
   PubMedGoogle Scholar
• Jabiry-Zieniewicz Z, Bobrowska K, Kaminski P, Wielgos M, Zieniewicz K, Krawczyk M. Low-dose hormonal contraception after liver transplantation. Transplant. Proc.39(5), 1530–1532 (2007).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. MMWR Recomm. Rep.59(RR4), 1–86 (2010).
   PubMedGoogle Scholar
• Zerner J, Doil KL, Drewry J, Leeber DA.Intrauterine contraceptive device failures in renal transplant patients. J. Reprod. Med.26(2), 99–102 (1981).
   PubMed Web of Science ®Google Scholar
• Lessan-Pezeshki M, Ghazizadeh S, Khatami MR et al. Fertility and contraceptive issues after kidney transplantation in women. Transplant. Proc.36(5), 1405–1406 (2004).
   PubMed Web of Science ®Google Scholar
• Stringer EM, Kaseba C, Levy J et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am. J. Obstet. Gynecol.197(2), 144.e1–e8 (2007).
   PubMed Web of Science ®Google Scholar
• Sheppard BL. Endometrial morphological changes in IUD users: a review. Contraception 1987 36(1), 1–10 (1987).
   PubMed Web of Science ®Google Scholar
• Seidegård J, Simonsson M, Edsbäcker S. Effect of an oral contraceptive on the plasma levels of budesonide and prednisolone and the influence on plasma cortisol. Clin. Pharmacol. Ther.67(4), 373–381 (2000).
   PubMedGoogle Scholar
• Armenti VT, Radomski JS, Moritz MJ et al. Report from the National Transplantation Pregnancy Registry (NTPR), outcomes of pregnancy after transplantation. Clin. Transpl.103–114 (2004).
   PubMedGoogle Scholar
• Mastrobattista JM, Gomez-Lobo V. Pregnancy after solid organ transplantation. Society for Maternal–Fetal Medicine. Obstet. Gynecol.112(4), 919–932 (2008).
   PubMed Web of Science ®Google Scholar
• Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA303(3), 235–241 (2010).
   PubMed Web of Science ®Google Scholar
• van der Steeg JW, Steures P, Eijkemans MJ et al. Obesity affects spontaneous pregnancy chances in subfertile, ovulatory women. Hum. Reprod.23(2), 324–328 (2008).
   PubMed Web of Science ®Google Scholar
• Holt VL, Cushing-Haugen KL, Daling JR. Body weight and risk of oral contraceptive failure. Obstet. Gynecol.99, 820–827 (2002).
   PubMed Web of Science ®Google Scholar
• Holt VL, Scholes D, Wicklund KG, Cushing-Haugen KL, Daling JR. Body mass index, weight, andoral contraceptive failure risk. Obstet. Gynecol.105, 46–52 (2005).
   PubMed Web of Science ®Google Scholar
• Dinger JC, Cronin M, Mohner S, Schellschmidt I, Minh TD, Westhoff C. Oral contraceptive effectiveness according to body mass index, weight, age, and other factors. Am. J. Obstet. Gynecol.201, 263.e1–e9 (2009).
   Web of Science ®Google Scholar
• Westhoff CL, Torgal AH, Mayeda ER et al. Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomized controlled trial. Obstet. Gynecol.116(2 Pt 1), 275–283 (2010).
   PubMed Web of Science ®Google Scholar
• Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil. Steril.77(Suppl. 2), S8–S13 (2002).
   Google Scholar
• Jamieson DJ, Hillis SD, Duerr A, Marchbanks PA, Costello C, Peterson. Complications of interval laparoscopic tubal sterilization: findings from the United States Collaborative Review of Sterilization. Obstet. Gynecol.96(6), 997–1002 (2000).
   PubMed Web of Science ®Google Scholar
• The Autoimmune Diseases Coordinating Committee. Progress in Autoimmune Diseases Research, Report to Congress. National Institutes of Health (2005).
   Google Scholar
• McCarty DJ, Manzi S, Medsger TA Jr, Ramsey-Goldman R, LaPorte RE, Kwoh CK. Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum.38, 1260–1270 (1995).
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Austin HA 3rd, Vaughn EM et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann. Intern. Med.119, 366 (1993).
   PubMed Web of Science ®Google Scholar
• Märker-Hermann E, Fischer-Betz R. Rheumatic diseases and pregnancy. Curr. Opin. Obstet. Gynecol.6, 458–465 (2010).
   Google Scholar
• Petri M, Kim MY, Kalunian KC et al. Combined oral contraceptives in women with systemic lupus erythematosus. N. Engl. J. Med.353, 2550–2558 (2005).
   PubMed Web of Science ®Google Scholar
• Sánchez-Guerrero J, Uribe AG, Jiménez-Santana L et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N. Engl. J. Med.353, 2539–2549 (2005).
   PubMed Web of Science ®Google Scholar
• Helmick CG, Felson DT, Lawrence RC et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States, Part I. Arthritis Rheum.58, 15–25 (2008).
   PubMed Web of Science ®Google Scholar
• Farr SL, Folger SG, Paulen ME, Curtis KM. Safety of contraceptive methods for women with rheumatoid arthritis: a systematic review. Contraception82(1), 64–71 (2010).
   PubMedGoogle Scholar
• Chi CC, Lee CW, Wojnarowska F, Kirtschig G. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst. Rev.3, CD007346 (2009).
   Google Scholar
• Longatto-Filho A, Hammes LS, Sarian LO et al. Hormonal contraceptives and the length of their use are not independent risk factors for high-risk HPV infections or high-grade CIN. Gynecol. Obstet. Invest.71(2), 93–103 (2011).
   PubMed Web of Science ®Google Scholar
• Veldhuijzen NJ, Snijders PJ, Reiss P, Meijer CJ, van de Wijgert JH. Factors affecting transmission of mucosal human papillomavirus. Lancet Infect. Dis.10(12), 862–874 (2010).
   PubMed Web of Science ®Google Scholar
• Haimovich S, Checa MA, Mancebo G, Fusté P, Carreras R. Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device. Menopause15(5), 1002–1004 (2008).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. Cancer J. Clin.58(2), 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Hankinson SE, Colditz GA, Manson JE et al. prospective study of oral contraceptive use and risk of breast cancer (Nurses’ Health Study, United States). Cancer Causes Control8(1), 65 (1997).
   PubMed Web of Science ®Google Scholar
• No authors listed. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies: Collaborative Group on Hormonal Factors in Breast Cancer. Lancet347, 1713–1727 (1996).
   PubMed Web of Science ®Google Scholar
• Valachis A, Tsali L, Pesce LL et al. Safety of pregnancy after primary breast carcinoma in young women: a meta-analysis to overcome bias of healthy mother effect studies. Obstet. Gynecol. Surv.65(12), 786–793 (2010).
   PubMed Web of Science ®Google Scholar
• Gaffield ME, Kapp N, Curtis KM. Combined oral contraceptive and intrauterine device use among women with gestational trophoblastic disease. Contraception80(4), 363–371 (2009).
   PubMedGoogle Scholar
• Garrett LA, Garner EI, Feltmate CM, Goldstein DP, Berkowitz RS. Subsequent pregnancy outcomes in patients with molar pregnancy and persistent gestational trophoblastic neoplasia. J. Reprod. Med.53(7), 481–486 (2008).
   PubMed Web of Science ®Google Scholar